Pharmacological cognitive enhancement-how neuroscientific research could advance ethical debate

Frontiers in Systems Neuroscience

Volumn 8, Issue JUNE, 2014, Pages

  Maslen, Hannah ^a   Faulmüller, Nadira ^b,c   Savulescu, Julian ^d  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c DELFT UNIVERSITY OF TECHNOLOGY   (Netherlands)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Brain function augmentation; Cheating; Cognitive enhancement; Ethics; Justice; Modafinil; Personalized enhancement; Ritalin

Indexed keywords

ATOMOXETINE; BROMOCRIPTINE; DEXAMPHETAMINE; DONEPEZIL; GALANTAMINE; GUANFACINE; MEMANTINE; METHYLPHENIDATE; MODAFINIL; PERGOLIDE; PLACEBO; REBOXETINE; RIVASTIGMINE;

ALERTNESS; ARTICLE; ATTENTION DEFICIT DISORDER; BRAIN FUNCTION; COGNITION; COGNITIVE DEFECT; DEPENDENT PERSONALITY DISORDER; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ETHICS; HUMAN; JUSTICE; LEARNING; MENTAL CONCENTRATION; META ANALYSIS (TOPIC); NEUROSCIENCE; PATHOLOGY; PERSUASIVE COMMUNICATION; PHARMACOLOGICAL STIMULATION; POLICY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPEECH INTELLIGIBILITY; WORKING MEMORY;

EID: 84902358030     PISSN: 16625137     EISSN: None     Source Type: Journal    
DOI: 10.3389/fnsys.2014.00107     Document Type: Article

References (72)

1. Academy of Medical Sciences, Royal Society, British Academy, Royal Academy of Engineering. (2012). Human Enhancement and the Future of Work (Report from Joint Workshop). Available online at:http://www.acmedsci.ac.uk/p47prid102.html#downloads (Accessed 22 May 2013).
2. Advokat, C. (2010). What are the cognitive effects of stimulant medication? Emphasis on adults with attentiondeficit/hyperactivity disorder. Neurosci. Biobehav. Rev. 34, 1256-1266. doi: 10.1016/j.neubiorev.2010.03.006
3. Beglinger, L. J., Gaydos, B. L., Kareken, D. A., Tangphao-Daniels, O., Siemers, E. R., and Mohs, R. C. (2004). Neuropsychological test performance in healthy volunteers before and after donepezil administration. J. Psychopharmacol. 18, 102-108. doi: 10.1177/0269881104040248
4. Beglinger, L. J., Tangphao-Daniels, O., Kareken, D. A., Zhang, L., Mohs, R., and Siemers, E. R. (2005). Neuropsychological test performance in healthy elderly volunteers before and after donepezil administration: a randomized, controlled study. J. Clin. Psychopharmacol. 25, 159-165. doi: 10.1097/01.jcp.0000155822.51962.b4
5. Bolt, I., and Schermer, M. (2009). Psychopharmacological enhancers: enhancing identity? Neuroethics 2, 103-111. doi: 10.1007/s12152-008-9031-7
6. Boot, B. P., Partridge, B., and Hall, W. (2012). Letter to the editor: better evidence for safety and efficacy is needed before neurologists prescribe drugs for neuroenhancement to healthy people. Neurocase 18, 181-184. doi: 10.1080/13554794.2011.588174
7. Bostrom, N., and Sandberg, A. (2009). Cognitive enhancement: methods, ethics, regulatory challenges. Sci. Eng. Ethics 15, 311-341. doi: 10.1007/s11948-009-9142-5
8. Bublitz, J. C., and Merkel, R. (2009). Autonomy and authenticity of enhanced personality traits. Bioethics 23, 360-374. doi: 10.1111/j.1467-8519.2009.01725.x
9. Bublitz, J. C., and Merkel, R. (2014). Crimes against minds: on mental manipulations, harms and a human right to mental self-determination. Crim. Law and Philos. 8, 51-77. doi: 10.1007/s11572-012-9172-y
10. Butler, A. C., Chapman, J. E., Forman, E. M., and Beck, A. T. (2006). The empirical status of cognitive-behavioral therapy: a review of meta-analyses. Clin. Psychol. Rev. 26, 17-31. doi: 10.1016/j.cpr.2005.07.003
11. Caldwell, J. A., and Caldwell, J. L. (2005). Fatigue in military aviation: an overview of us military-approved pharmacological countermeasures. Aviat. Space Environ. Med. 76(7 Suppl.), C39-C51.
12. Chatterjee, A. (2004). Cosmetic neurology the controversy over enhancing movement, mentation, and mood. Neurology 63, 968-974. doi: 10.1212/01.WNL.0000138438.88589.7C
13. DeGrazia, D. (2005). Human Identity and Bioethics. Cambridge: Cambridge University Press.
14. de Jongh, R., Bolt, I., Schermer, M., and Olivier, B. (2008). Botox for the brain: enhancement of cognition, mood and pro-social behavior and blunting of unwanted memories. Neurosci. Biobehav. Rev. 32, 760-776. doi: 10.1016/j.neubiorev.2007.12.001
15. DeSantis, A. D., Webb, E. M., and Noar, S. M. (2008). Illicit use of prescription ADHD medications on a college campus: a multimethodological approach. J. Am. Coll. Health 57, 315-324. doi: 10.3200/JACH.57.3.315-324
16. Drabiak-Syed, K. (2011). Reining in the pharmacological enhancement train: we should remain vigilant about regulatory standards for prescribing controlled substances. J. Law Med. Ethics 39, 272-279. doi: 10.1111/j.1748-720X.2011.00596.x
17. Dresler, M., Sandberg, A., Ohla, K., Bublitz, C., Trenado, C., Mroczko-Wasowicz, A., et al. (2012). Non-pharmacological cognitive enhancement. Neuropharmacology 64, 529-543. doi: 10.1016/j.neuropharm.2012.07.002
18. Elliott, C. (1999). A Philosophical Disease: Bioethics, Culture and Identity. Psychology Press.
19. Elliott, R., Sahakian, B. J., Matthews, K., Bannerjea, A., Rimmer, J., and Robbins, T. W. (1997). Effects of methylphenidate on spatial working memory and planning in healthy young adults. Psychopharmacology 131, 196-206. doi: 10.1007/s002130050284
20. European Medicines Agency. (2010). Questions and Answers on the Review of Medicines Containing Modafinil. EMA/CHMP/460496/2010. Available online at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Modafinil/human_referral_000236.jsp
21. Farah, M. J., Smith, M. E., Ilieva, I., and Hamilton, R. H. (2014). Cognitive enhancement. Wiley Interdiscipl. Rev. Cogn. Sci. 5, 95-103. doi: 10.1002/wcs.1250
22. Faulmüller, N., Maslen, H., and Santoni de Sio, F. (2013). The indirect psychological costs of cognitive enhancement. Am. J. Bioeth. 13, 45-47. doi: 10.1080/15265161.2013.794880
23. Fox, D. (2005). Safety, Efficacy, and Authenticity: The Gap between Ethics and law in FDA Decisionmaking. Available online at: http://heinonline.org/HOL/Page?handle=hein.journals/mslr2005&div=44&g_sent=1&collection=journals#1147
24. Franke, A. G., Bonertz, C., Christmann, M., Huss, M., Fellgiebel, A., Hildt, E., et al. (2011). Non-medical use of prescription stimulants and illicit use of stimulants for cognitive enhancement in pupils and students in Germany. Pharmacopsychiatry 44, 60-66. doi: 10.1055/s-0030-1268417
25. Fukuyama, F. (2002). Our Post human Future: Consequences of the Biotechnology Revolution. New York, NY: Farrar, Straus and Giroux.
26. Goodman, R. (2010). Cognitive enhancement, cheating, and accomplishment. Kennedy Inst. Ethics J. 20, 145-160. doi: 10.1353/ken.0.0309
27. Goold, I., and Maslen, H. (2014). Must the surgeon take the pill? Negligence duty in the context of cognitive enhancement. Mod. Law Rev. 77, 60-86. doi: 10.1111/1468-2230.12056
28. Greely, H., Sahakian, B., Harris, J., Kessler, R. C., Gazzaniga, M., Campbell, P., et al. (2008). Towards responsible use of cognitive-enhancing drugs by the healthy. Nature 456, 702-705. doi: 10.1038/456702a
29. Greely, H. T. (2010). "Enhancing brains: what are we afraid of?" in Cerebrum: the Dana Forum on Brain Science, Vol. 2010 (Dana Foundation). Available online at: http://dana.org/news/cerebrum/detail.aspx?id=28786
30. Gron, G., Kirstein, M., Thielscher, A., Riepe, M. W., and Spitzer, M. (2005). Cholinergic enhancement of episodic memory in healthy young adults. Psychopharmacology 182, 170-179. doi: 10.1007/s00213-005-0043-2
31. Hall, W. D., and Lucke, J. C. (2010) Enhancement uses of neuropharmaceuticals: more caution and skepticism needed. Addiction 105, 2041-2043. doi: 10.1111/j.1360-0443.2010.03211.x
32. Husain, M., and Mehta, M. A. (2011). Cognitive enhancement by drugs in health and disease. Trends Cogn. Sci. 15, 28-36. doi: 10.1016/j.tics.2010.11.002
33. Juengst, E. T. (1998). "What does enhancement mean?, " in Enhancing Human Traits: Ethical and Social Implications, ed E. Parens (Georgetown University press), 29-47.
34. Juth, N. (2011). "Enhancement, autonomy, and authenticity, " in Enhancing Human Capacities, eds J. Savulescu, R. ter Meulen, and G. Kahane (Oxford: Wiley-Blackwell), 34-48.
35. Kahane, G., and Savulescu, J. (2013). Normal human variation: refocussing the enhancement debate. Bioethics. doi: 10.1111/bioe.12045. [Epub ahead of print].
36. Kass, L. (2003). Ageless bodies, happy souls. New Atlantis 1, 9-28.
37. Kroutil, L. A., Van Brunt, D. L., Herman-Stahl, M. A., Heller, D. C., Bray, R. M., and Penne, M. A. (2006). Nonmedical use of prescription stimulants in the United States. Drug Alcohol Depend. 84, 135-143. doi: 10.1016/j.drugalcdep.2005.12.011
38. Lanni, C., Lenzken, S. C., Pascale, A., Del Vecchio, I., Racchi, M., Pistoia, F., et al. (2008). Cognition enhancers between treating and doping the mind. Pharmacol. Res. 57, 196-213. doi: 10.1016/j.phrs.2008.02.004
39. Maher, B. (2008). Poll results: look who's doping. Nature 452, 674-675. doi: 10.1038/452674a
40. Mehta, M. A., Owen, A. M., Sahakian, B. J., Mavaddat, N., Pickard, J. D., and Robbins, T. W. (2000). Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain. J. Neurosci. 20:RC65.
41. Mignot, E. (2010). "Narcolepsy: genetic predisposition and pathophysiology, " in Narcolepsy: A Clinical Guide, eds M. Goswami, S. R. Pandi-Perumal, and M. J. Thorpy (New York, NY: Springer), 3-21. doi: 10.1007/978-1-4419-0854-4_1
42. Minzenberg, M. J., and Carter, C. S. (2008). Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology 33, 1477-1502. doi: 10.1038/sj.npp.1301534
43. Maier, L. J., Liechti, M. E., Herzig, F., and Schaub, M. P. (2013). To dope or not to dope: neuroenhancement with prescription drugs and drugs of abuse among Swiss university students. PLoS ONE 8:e77967. doi: 10.1371/journal.pone.0077967
44. Maslen, H., Douglas, T., Cohen Kadosh, R., Levy, N., and Savulescu, J. (2014). The regulation of cognitive enhancement devices: extending the medical model. J. Law Biosci. 1, 68-93. doi: 10.1093/jlb/lst003
45. Maslen, H., Santoni de Sio, F., and Faulmüller, N. (in press). "With cognitive enhancement comes great responsibility?, " in Responsible Innovation, Vol. 2, eds B. J. Koops et al. (Dordrecht: Springer).
46. Müller, U., Steffenhagen, N., Regenthal, R., and Bublak, P. (2004). Effects of modafinil on working memory processes in humans. Psychopharmacology 177, 161-169. doi: 10.1007/s00213-004-1926-3
47. Outram, S. M. (2010). The use of methylphenidate among students: the future of enhancement?. J. Med. Ethics 36, 198-202. doi: 10.1136/jme.2009.034421
48. Parens, E. (1998). Is better always good?: the enhancement project. Hastings Center Rep. 28, s1-s17. doi: 10.2307/3527981
49. President's Council on Bioethics. (2003). Beyond Therapy. Washington, DC: U.S. Government Printing Office, 253.
50. Ragan, C. I., Bard, I., and Singh, I. (2013). What should we do about student use of cognitive enhancers? An analysis of current evidence. Neuropharmacology 64, 588-595. doi: 10.1016/j.neuropharm.2012.06.016
51. Repantis, D. (2013). "Psychopharmacological neuroenhancement: evidence on safety and efficacy, " in Cognitive Enhancement, eds E. Hildt and A. G. Franke (Dordrecht: Springer), 29-38.
52. Repantis, D., Schlattmann, P., Laisney, O., and Heuser, I. (2010). Modafinil and methylphenidate for neuroenhancement in healthy individuals: a systematic review. Pharmacol. Res. 62, 187-206. doi: 10.1016/j.phrs.2010.04.002
53. Rose, S., and Curry, T. (2010). Fatigue countermeasures, and performance enhancement in resident physicians-reply. Mayo Clin. Proc. 85, 301-302. doi: 10.4065/mcp.2009.0704
54. Sabin, J. E., and Daniels, N. (1994). Determining "medical necessity" in mental health practice. Hastings Center Rep. 24, 5-13. doi: 10.2307/3563458
55. Sandberg, A. (2011). "Cognition enancement: upgrading the brain, " in Enhancing Human Capacities, eds J. Savulescu, R. ter Meulen, and G. Kahane (Oxford: Wiley-Blackwell), 71-91.
56. Sandberg, A., and Savulescu, J. (2011). "The social and economic impacts of cognitive enhancements, " inEnhancing Human Capacities, eds J. Savulescu, R. ter Meulen, and G. Kahane (Oxford: Wiley-Blackwell), 93-112.
57. Santoni de Sio, F., Faulmüller, N., Savulescu, J., and Vincent, N. A. (in press). "Why less praise for enhanced performance? Moving beyond responsibility-shifting, authenticity, and cheating to a nature of activities approach, " in Cognitive Enhancement: Ethical and Policy Implications in International Perspectives, eds F. Jotterand and V. Dubljevic (Oxford: Oxford University Press).
58. Savulescu, J., Sandberg, A., and Kahane, G. (2011). "Well-being and enhancement, " in Enhancing Human Capacities, J. Savulescu, R. ter Meulen, and G. Kahane (Oxford: Wiley-Blackwell), 3-18.
59. Schelle, K. J., Faulmüller, N., Caviola, L., and Hewstone, M. (2014). Attitudes towards pharmacological cognitive enhancement-a review. Front. Syst. Neurosci. 8:53. doi: 10.3389/fnsys.2014.00053
60. Schermer, M. (2008). Enhancements, easy shortcuts, and the richness of human activities. Bioethics 22, 355-363. doi: 10.1111/j.1467-8519.2008.00657.x
61. Schermer, M., and Bolt, I. (2011). "What's in a name? ADHD and the gray area between treatment and enhancement, " in Enhancing Human Capacities, eds J. Savulescu, R. ter Meulen, and G. Kahane (Oxford: Wiley-Blackwell), 179-193.
62. Singh, I. (2005). Will the "real boy" please behave: dosing dilemmas for parents of boys with ADHD. Am. J. Bioeth. 5, 34-47. doi: 10.1080/15265160590945129
63. Smith, M. E., and Farah, M. J. (2011). Are prescription stimulants "smart pills"? The epidemiology and cognitive neuroscience of prescription stimulant use by normal healthy individuals. Psychol. Bull. 137, 717-741. doi: 10.1037/a0023825
64. Taylor, C. (1991). The Ethics of Authenticity. Cambridge, MA: Harvard University Press.
65. Thomas, R. J., and Kwong, K. (2006). Modafinil activates cortical and subcortical sites in the sleep-deprived state. Sleep 29, 1471-1481.
66. Tricco, A. C., Soobiah, C., Berliner, S., Ho, J. M., Ng, C. H., Ashoor, H. M., et al. (2013). Efficacy and safety of cognitive enhancers for patients with mild cognitive impairment: a systematic review and meta-analysis. Can. Med. Assoc. J. 185, 1393-1401. Doi: 10.1503/cmaj.130451
67. Turner, D. C., Robbins, T. W., Clark, L., Aron, A. R., Dowson, J., and Sahakian, B. J. (2003). Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology 165, 260-269. doi: 10.1007/s00213-002-1250-8
68. Volkow, N. D., Wang, G. J., Fowler, J. S., Telang, F., Maynard, L., Logan, J., et al. (2004). Evidence that methylphenidate enhances the saliency of a mathematical task by increasing dopamine in the human brain. Am. J. Psychiatry. 161, 1173-1180. doi: 10.1176/appi.ajp.161.7.1173
69. Warren, O. J., Leff, D. R., Athanasiou, T., Kennard, C., and Darzi, A. (2009). The neurocognitive enhancement of surgeons: an ethical perspective. J. Surg. Res. 152, 167-172. doi: 10.1016/j.jss.2007.12.761
70. Wesensten, N. J., Killgore, W. D., and Balkin, T. J. (2005). Performance and alertness effects of caffeine, dextroamphetamine, and modafinil during sleep deprivation. J. Sleep Res. 14, 255-266. doi: 10.1111/j.1365-2869.2005.00468.x
71. White, B. P., Becker-Blease, K. A., and Grace-Bishop, K. (2006). Stimulant medication use, misuse, and abuse in an undergraduate and graduate student sample. J. Am. Coll. Health 54, 261-268. doi: 10.3200/JACH.54.5.261-268
72. Yesavage, J. A., Mumenthaler, M. S., Taylor, J. L., Friedman, L., O'Hara, R., Sheikh, J., et al. (2002) Donepezil and flight simulator performance: effects on retention of complex skills. Neurology 59, 123-125. doi: 10.1212/WNL.59.1.123